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Abstract 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause 
of kidney failure and affects up to 12 million people worldwide. Germline mutations in two 
genes, PKD1 or PKD2, account for almost all patients with ADPKD. The ADPKD proteins, 
polycystin-1 (PC1) and polycystin-2 (PC2), are regulated by post-translational modifications 
(PTM), with phosphorylation, glycosylation and proteolytic cleavage being the best described 
changes. A few PTMs have been shown to regulate polycystin trafficking, signalling, 
localisation or stability and thus their physiological function. A key challenge for the future 
will be to elucidate the functional significance of all the individual PTMs reported to date. 
Finally, it is possible that site-specific mutations that disrupt PTM could contribute to 
cystogenesis although in the majority of cases, confirmatory evidence is awaited. 
 
Introduction 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited renal 
disorder, affecting over 12 million people worldwide, with a prevalence of ca. 1/1,000 [1]. It 
is caused by germline mutations in one of two genes: PKD1 (80%) and PKD2 (15%) encoding 
the proteins PC1 and PC2 respectively. As ~7% of cases are genetically unresolved, the 
existence of a third locus (PKD3) has been postulated. Whole exosome sequencing of these 
families have identified mutations in two additional genes, GANAB and DNAJB11, which 
typically result in a late-onset atypical phenotype. GANAB, encodes the glucosidase II alpha 
subunit, and may account for   of ADPKD [2]. DNAJB11 is responsible for the regulation 
of normal protein folding and assembly in the ER [3]. Mutations in both genes result in a 
defect in the maturation and trafficking of PC1. 
Disease is believed to occur by a loss of function mechanism i e  by two hit  or 
haploinsufficiency models [4]  In the two hit  model  cystogenesis occurs in cells carrying a 
germline mutation on one allele; however a somatic mutation to the other allele is required 
to trigger cyst formation. The alternative hypothesis of cyst formation is haploinsufficiency, 
which supposes that mutations in one allele may be sufficient to initiate cyst formation and 
other non-cystic features in ADPKD. This is a gene-dosage-dependent mechanism in which 
gene expression level may be more variable due to the presence of only one functional allele. 
Lowering the level of PC1 or/and PC2, below a tissue specific threshold could predispose renal 
epithelial cells to stochastic events which trigger cyst initiation [5]. Human PKD1 may be 
particularly sensitive to a dosage reduction as abnormal splicing across intron 21 and 22 
typically results in a significant number of mRNA transcripts (28.8-61.5%) terminating early 
[6].  
In typical adult-onset disease, thousands of renal cysts are found in most ADPKD patients by 
the fifth decade, while only a few are evident before 20 years of age. However, in rare very-
early onset cases (under 2 years of age), the phenotype can be severe and is associated with 
a high prevalence of biallelic or compound heterozygous mutations in PKD1 [7, 8]. A high rate 
of somatic mutation in PKD1 has been reported in end-stage human ADPKD kidney cysts 
indicating that this could contribute to cyst progression in typical late-onset disease [9]. 
 
The polycystin proteins 
Polycystin-1 
PC1 is a 4,303 amino acid protein with a predicted unglycosylated molecular weight of 
462kDa. Its topology is that of a Type 1 receptor consisting of a large N-terminal extracellular 
region, a transmembrane region (11 predicted domains) and a short C-terminus [10]. The 
extracellular N-terminus (3000 aa) has a highly modular structure and contains various 
domains (LRR, WSC, C-lectin, LDL-A, PKD, REJ, GAIN) which give it the ability to perform 
multiple functions including cell recognition, cell-cell and cell-matrix adhesion [11-14].  Cis-
proteolytic cleavage mediated by the GAIN domain at the conserved G-protein coupled 
receptor proteolytic cleavage site (GPS) generates N- and C-terminal fragments (NTF, CTF) 
which remain tethered by non-covalent bonds [15].  Although PC1 has been localised to the 
primary cilium where it is proposed to act as a mechanoreceptor [16], a significant body of 
work has also reported its localisation to the lateral plasma membrane where a role in 
mediating and stabilising cell adhesion has been proposed [12, 17]. In this context, the 
presence of the GAIN domain typical of adhesion-GPCRs (ADGR) is suggestive that the latter 
could be its main site of action [18]. Overall PC1 is still considered an orphan receptor though 
experimental evidence that it could act as a co-receptor for Wnt and signal through PC2 in a 
non-canonical Wnt pathway (Wnt/Ca2+) has been demonstrated in some systems [19, 20]. 
Isolated PC1 domains (C-type lectin, LRR) have been shown to bind several extracellular 
matrix proteins in vitro [21, 22]. 
The polycystin-1 lipoxygenase A-toxin (PLAT) domain is evolutionarily conserved in all 
orthologues and paralogues of PC1 [23]. Located in the first intracellular loop, it may act as a 
protein scaffold regulating the intracellular signalling, trafficking and endocytosis of PC1 [24]. 
The PC1 intracellular C-terminus (CT1) comprising the last 200 amino acids is the most 
extensively studied region and contains several key motifs including a coil-coiled region which 
mediates interaction between PC1 and PC2 [17, 25].  
 
Polycystin-2 
PC2 is a Type 2 968 amino acid protein (109 kDa) with six transmembrane domains and 
intracellular N- and C-termini [26].  PC2 (TRPP2) has been adopted into the Transient Receptor 
Potential (TRP) channel superfamily as the founding member of the TRP(P) subfamily [27]. 
Although there is good evidence that PC1 and PC2 form a functional heterodimeric complex, 
its main location and site of action relevant to cyst formation remain controversial [5]. Similar 
to PC1, PC2 has been localised to primary cilia and the lateral plasma membranes [16, 17, 28, 
29]. However, PC2 is predominantly located in the ER as well as at the centrosomes, mitotic 
spindles and sorting endosomes [17, 20, 30-32].  
The localisation of PC2 and PC1 to primary cilia has led to ADPKD as a disease being adopted 
into the group of diseases known as ciliopathies  Whether loss of cilia-localised PC2 in 
isolation is sufficient to lead to cyst formation remains uncertain. In addition, PC2 may 
function as an ER Ca2+ -regulated Ca2+-release channel, in association with IP3R and RyR in 
different cell types [33, 34]. There is also biochemical and functional evidence that PC2/TRPP2 
can with other TRP channel subunits such as TRPC1, TRPV4, TRPM3 to form channels with 
unique properties [35-37]. The relevance of these TRPP combinations to the pathogenesis of 
cystic disease remains undefined.  
The interacting motifs and stoichiometry for the formation of a PC1 and PC2 complex have 
been defined. PC2 has been shown to oligomerise via a coiled-coil domain in its C-terminus 
(CT2) to form trimers or dimers and this step appears to be critical for PC1 binding via a coil-
coiled domain in CT1 [38, 39]. PC2 is essential for PC1 maturation and its surface (and cilia) 
localisation and vice-versa [40]. However, the trafficking of PC2 into cilia does not always 
depend on PC1 expression or binding [41]. Co-regulation of PC2 by PC1 and vice-versa have 
been reported in some experimental systems [42-44]. The proposed role of PC1 as a flow-
activated mechanoreceptor regulating PC2 channel opening in primary cilia has been disputed 
by recent studies [16, 45, 46]. Finally, although there is agreement that PC2 is a Ca2+ 
permeable channel, there is disagreement about its ion selectivity (monovalent v divalent 
ions) and mode of activation or inactivation by Ca2+ depending on the model systems used 
[47]. One possibility is that these may differ between different subpopulations of PC2/TRPP2 
or in different locations. For instance, a recent study has proposed a role for ER PC2 in 
protection from cellular stress [48, 49]. 
Several PC2 structures including one complexed with PC1 have been recently published. Shen 
et al. were the first to report a polycystin domain  in the large first extracellular loop, 
covalently linked to the first and second helices, and proposed a role for this domain in 
channel assembly and modulation [50]. Grieben et al. recently performed the first 
crystallisation of the full closed version of the protein, giving more insights into its structure 
and function [51]. They confirmed the existence of the polycystin domain, which they 
renamed the TOP domain (standing for Tetragonal Opening for Polycystins). Wilkes et al. 
recently reported the presence of two PC  conformational states  an open  conformation 
where the lipid mediated interaction between the TOP and C-terminal domain lead to a larger 
opening of the funnel and a more closed  state which restricts the passage of ions such as 
Ca2+, Na+ and K+ [52]. Ca2+ entry was thought to be mediated through a pore formed between 
the fifth and sixth transmembrane domains of the protein [51]. Of interest, a cryo-EM 
structure of truncated human PC1 (3049-4169aa) and PC2 (185-723aa) proteins 
demonstrated a 1:3 stoichiometry of the PC1/PC2 complex [53]. In this study, PC1 was found 
to interact with PC2 via an extracellular voltage gated ion channel (VGIC) fold providing a 
second level of interaction besides the C-terminal interactions previously reported. 
The function of several motifs in the N- and C-termini were however not clarified in these 
structural studies. For instance, the EF-hand motif of PC2 forms a pocket-like structure that 
binds to Ca2+ ions and could modify the conformation of the C-terminus: how this regulates 
channel function is not known [54]. Similarly, the regulatory functions of the phosphorylation 




In the past few decades, it has become apparent that the human proteome is vastly more 
complex than the human genome (Figure 1). While the human genome comprises between 
20,000 and 25,000 genes, the total number of proteins in the human proteome has been 
estimated at over 1 million demonstrating that single genes can encode multiple protein 
isoforms. Genomic recombination, transcription initiation at alternative promoters, 
differential transcription termination, and alternative splicing of the transcript are 
mechanisms that can generate different mRNA transcripts from a single gene. 
The increase in complexity from the level of the genome to the proteome is amplified by 
protein post-translational modifications (PTMs). PTMs are chemical modifications that play a 
key role in protein function regulating its activity, localisation, stability and interaction with 
other cellular molecules such as proteins, nucleic acids, lipids and cofactors.  
Post-translational modifications can occur on the amino acid side chains or at the protein's C- 
or N-termini (Table 1). They can extend the chemical repertoire of the 20 standard amino 
acids by modifying an existing functional group or introducing a new one such as phosphate. 
Phosphorylation is a very common mechanism for regulating the activity of enzymes and is 
the most common post-translational modification. Many eukaryotic and prokaryotic proteins 
also have carbohydrate molecules attached to them, a process called glycosylation which can 
promote protein folding, improve stability as well as serving regulatory functions. Attachment 
of lipid molecules, known as lipidation, often targets a protein or part of a protein attached 
to the cell membrane.  
Other forms of PTM consist of proteolytic cleavage, as in processing a propeptide to a mature 
form or removing the initiator methionine residue. The formation of disulfide (covalent) 
bonds between cysteine residues may also be referred to as a PTM. For instance, the peptide 
hormone insulin is cut twice after disulfide bonds are formed, and a propeptide is removed 
from the middle of the chain resulting in a protein consisting of two polypeptide chains 
connected by disulfide bonds.  
Sites that often undergo post-translational modification are those that have a functional 
group that can serve as a nucleophile in the reaction: the hydroxyl groups of serine, threonine, 
and tyrosine; the amine forms of lysine, arginine, and histidine; the thiolate anion of cysteine; 
the carboxylates of aspartate and glutamate; and the N- and C-termini. In addition, although 
the amide of asparagine is a weak nucleophile, it can serve as an attachment point for glycans. 
Rarer modifications can occur at oxidized methionines and at some methylenes in side chains.  
Some types of PTM occur as the consequence of oxidative stress. Carbonylation is one 
example that targets the modified protein for degradation and can result in the formation of 
protein aggregates. Specific amino acid modifications can be used as biomarkers indicating 
oxidative damage.  
 
Post-translational modification of polycystin protein and their functional significance 
Since the identification of the polycystin proteins, a great deal of effort has been made to 
understand their function within the cellular environment. It has become clear that the 
functions of these proteins could be regulated by distinct post-translational modifications. By 
far the most studied modification is phosphorylation but glycosylation, proteolytic cleavage, 
ubiquitination and lipidation have also been described. This section will describe these 




Phosphorylation of PC2 at multiple residues has been detected by mass spectrometry in 
several large-scale phosphoproteomic studies. The majority of these residues are highly 
conserved in vertebrates suggesting they may be essential for polycystin function although to 
date, only a few have been experimentally verified (https://www.phosphosite.org) (Figure 2). 
A summary of how phosphorylation of PC2 may regulate key cellular functions such as its 
subcellular localisation and/or trafficking, calcium permeability and cell cycle regulation is 
summarised in Figure 3.  
 
Serine 812 
The first phosphorylation site within the C-termini of PC2 was identified at Ser812 and this 
remains the most studied residue [55]. Phosphorylation at this site is important for channel 
function; loss of phosphorylation resulted in reduced sensitivity to PC2 channel activation by 
intracellular Ca2+ in ER-enriched liposomes [55]. A second study demonstrated a role for Ser812 
phosphorylation in regulating PC2 trafficking [56].  Ser812 is located in a cluster of acidic amino 
acid residues which were found to mediate interaction between polycystin-2 and the 
phosphofurin acidic cluster sorting (PACS) proteins, PACS-1 and PACS-2. Interaction with 
these PACS proteins proved essential for the retrograde trafficking of PC2 between the 
plasma membrane, Golgi and ER. Binding of PACS to PC2 was dependent on CK2 
phosphorylation at Ser812; mutation of Ser812 to alanine or disruption of the acidic cluster 
weakened PACS binding resulting in translocation of PC2 to the lateral plasma membrane. 
These observations were later confirmed in a zebrafish model [57]. In a third study, a 
phosphomimic Ser812D C-terminal protein (679-968aa) had lower affinity binding to PIGEA14 
compared to wild-type PC2, potentially regulating anterograde PC2 transport between the ER 
and Golgi [58, 59]. Finally, phosphorylation at Ser812 was reported to be important for PC2 
binding to ID2 (inhibitor of DNA binding 2), a member of the ID family of helix-loop-helix (HLH) 
transcription factors [60]. Phosphorylated PC2 bound ID2 retaining it in the cytoplasm, 
preventing its effect on p21 transcription leading to cell-cycle progression. 
 
Other serine residues 
Serine 76/80 
Although an initial study reported that PC2 was only phosphorylated at a single residue 
(Ser812) [55], a second GSK3-recognition site was next identified at Ser76 with a potential CK1 
priming site at Ser80 [61]. This phosphorylation event was required for PC2 trafficking to (or 
retention at) the lateral plasma membrane but not to primary cilia in kidney epithelial cells. 
The inability of a phosphodeficient Ser76 mutant to rescue the cystic phenotype in the 
zebrafish Pkd2 pronephric kidney further confirmed its functional significance [61].  
Serine 801 
A third PC2 phosphorylated residue (Ser801) mediated by protein kinase D (PrKD) was shown 
to be critical for PC2-mediated ER Ca2+ release and in mediating PC2 regulation of proliferation 
[62]. Interestingly, a reported missense mutation, Ser804N, which lies within the PrKD 
consensus sequence abolished Ser801 phosphorylation [62, 63]. Phosphorylation at Ser801 by 
PrKD thus appears to be essential for PC2 channel function in the ER in response to growth 
factor stimulation.   
Serine 829 
A fourth site at Ser829 was identified by several groups. In the first study, AurA kinase was 
identified as the relevant kinase and was shown to reduce the ability of PC2 to limit the 
amplitude of ER Ca2+ release in kidney epithelial cells [64]. A second study reported that 
Protein kinase G (PKG) could phosphorylate PC2 at Ser829, inhibiting flow induced Ca2+ influx 
in M1-CCD cells; the authors proposed Ser721 as a second relevant PKG site [65]. Finally, 
protein kinase A (PKA) was shown to phosphorylate PC2 at Ser829 [44, 66]. In this study, Ser829 
phosphorylation led to enhanced ATP-dependent ER Ca2+ release and loss of growth 
suppression in cycling cells. Of significance, constitutive Ser829 phosphorylation detected with 
a phosphospecific antibody was observed in PC1 null or mutant cells. The molecular basis of 
this is the recruitment of protein phosphatase 1 (PP1) by the PC1 C-terminus, a function that 
is lost when PC1 is mutated [67]. This observation suggested a different paradigm of disease 
pathogenesis with an inhibitory rather than a cooperative relationship between PC1 and PC2 
[44].  
Other potential sites 
Studies of the worm PC2 homologue has shown that phosphorylation of Ser534 by CK2 was 
important in PC2 ciliary localisation and its function during male mating behaviour [68]. 
Evolutionary conservation of this CK2 site in human PC2 (Thr683) suggests it s potential 
importance although this has yet to be shown experimentally. 
 
Polycystin-1 
The functional significance of PC1 phosphorylation is less well defined although several 
potential sites of interest have been reported. Tyrosine phosphorylation of PC1 was first 
demonstrated implicating a role for tyrosine phosphorylation in PC1-mediated focal adhesion 
complexes [69, 70]. C-src, FAK, PKA and a novel kidney cAMP-dependent kinase protein kinase 
X (PRKX) can phosphorylate CT1 in vitro. Site-directed mutagenesis identified Tyr4237 as the 
specific target site for c-src, Ser4252 and Ser4169 as specific target sites for PKA [71-73] and 
Ser4166 as the specific target site for PRKX [72]. Outside the C-terminus, PC1 can be 
phosphorylated at Ser3164 within the PLAT domain by PKA [24]. This event reduces its binding 
affinity to PI4P and recruits β-arrestins and the clathrin adaptor AP2 to trigger PC1 
internalization. Finally, PC1 in ADPKD cells has been reported to be hyperphosphorylated (by 
phospholabelling with 32P) and proposed to contribute to the disruption of a PC1/E-cadherin 
complex [74]. Although the relevant sites were not identified in this paper, an increase in PC1 
phosphorylation could result from loss of PP1 binding to CT1, similar to what has been  
observed for CT2 (see above, Figure 3). 
 
Other post-translational modifications of polycystins 
Glycosylation 
The polycystin proteins are highly glycosylated. Sequence predictions indicate 60 N-linked 
sites for PC1 and experimentally, several different glycosylated forms of endogenous PC1 
have been identified. Treatment with PNGase F (to cleave N-linked sugars) and 
endoglycosidase H (Endo H) (to differentiate high-mannose sugars) led to the identification 
of Endo H resistant and sensitive forms of PC1. An Endo H sensitive and an Endo H-resistant 
form of PC1 were found to interact with PC2, with the latter enriched in plasma membrane 
fractions [17]. It has been estimated that 50% of PC1 is EndoH resistant and localised to the 
cell surface and that PC2 is critical for this trafficking [40].  
Sequence predictions indicate 5 N-linked sites for PC2 (all in the first extracellular loop). 
Unexpectedly, no EndoH resistant fraction has been consistently found suggesting that the 
majority of (Endo H-sensitive) PC2 is retained within the ER where it exerts its major functions 
[17, 30].  An alternative mechanism proposes that a small fraction of PC2 traffics from the cis-
Golgi to the cilium without going through the classical secretory pathway [75], possibly 
mediated by an N-terminal RVxP motif (Figure 3) [41]. Nonetheless, PC2 in human urine 
extracellular vesicles has been reported to be predominantly EndoH-resistant [76]. Similarly, 
another group reported a minor EndoH-resistant PC2 cilia fraction complexed with PC1, that 
transited the Golgi via a Rabep1/GGA1/Arl3-dependent ciliary targeting mechanism [77]. N-
glycosylation is linked to protein stability and mutation of PRKSCH (glucosidase II  subunit) 
reduces the abundance of PC2 probably through effects on protein folding and/or translation 




A key post-translational modification of PC1 is the ability to undergo cleavage via a GPCR 
proteolysis site (GPS) motif situated distal to the REJ-GAIN domain [79]. GPS cleavage of PC1 
has been shown to regulate intracellular trafficking, localisation and function of the protein 
[80-83]. Cleavage is thought to occur shortly after ER processing and results in the formation 
of two distinct fragments (NTF, CTF) that are non-covalently associated (Figure 4). The 
functional importance of this PTM in vivo was demonstrated by the characterisation of a 
knock-in mutant mouse (Pkd1V/V) with a missense mutation (T3041V) disrupting the GPS 
cleavage site [84]. Surprisingly, although GPS cleavage was completely prevented, mutant 
Pkd1V/V mice had a hypomorphic phenotype, characterised by delayed onset of cystogenesis, 
predominant distal tubule involvement and lack of extrarenal cysts indicating a possible role 
for the uncleaved form in prenatal life, in other tubular segments and extrarenal tissues. GPS 
cleavage does not however appear to be essential for PC1 maturation [81]. 
An essential role for GPS cleavage in the cilia trafficking of PC1 has been proposed [77] 
although cilia localisation can be normal in some mutants [85, 86]. Around 30% of all reported 
pathogenic PKD1 mutations are located in the REJ-GAIN region with the potential to disrupt 
GPS cleavage (http://pkdb.mayo.edu) [15]. 
 
Other cleavage events 
Several groups have reported that CT1 may undergo proteolytic cleavage to release smaller 
fragments (14, 32, 100kDa) (Figure 4) that translocate to the nucleus to regulate gene 
transcription, in co-operation with other transcription factors such as STAT6, STAT3 and 
TCF/ -catenin [87-89]. A G-protein activation motif has been shown to be involved in the 
activation of transcription factor AP-1 mediated signalling [90, 91]: mutation of this motif 
(L4132Delta) leads to cyst formation [92]. Intriguingly, a CT1 fragment has been identified in 
mitochondria and could regulate mitochondrial morphology and function [93]. One caveat is 
that all of these studies were performed using heterologous or recombinant PC1. However, a 
recent study of native PC1 in human urine extracellular vesicles identified three other 
proteolytic cleavage sites, two of which could generate PC1 fragments similar in size to those 
previously reported (11, 94kDa) (Figure 4) [76]. Similar to PC1, a low percentage of PC2 (13%) 
was also found to be cleaved proximal to the coiled-coil domain (aa835-873, CC2) [76]. Unlike 
GPS cleavage, the functional relevance of these cleavage events is unclear. 
 
Ubiquitination 
Ubiquitin is conjugated to a lysine residue in the substrate protein by a series of enzymes 
either singly (mono) or as part of a chain (poly) ubiquitination. Ubiquitination can target a 
protein for degradation via the proteasome and lysosome, alter their cellular location, affect 
their activity, and promote or prevent protein interactions. PC2 has been reported to be 
ubiquitinated following interaction with Herp and ATPase p97, components of the ER-
associated degradation (ERAD) pathway [94]. Of interest, this PTM is inhibited by PRKCSH, the 
 subunit of glucosidase II, which when mutated results in Autosomal Dominant Polycystic 
Liver Disease (PCLD1) [95]. 
TAZ, a core component of the Hippo pathway and an adaptor protein in the E3 ubiquitin ligase 
complex can also target PC2 for degradation [96, 97]. The kinase Nek1 phosphorylates TAZ at 
a site essential for the ubiquitination and proteosomal degradation of PC2. Loss of TAZ or 
mutations in Nek1 are associated with renal cysts in vivo in the context of increased PC2 
expression. PKD2 transgenic mice, like PKD1 transgenic mice, develop PKD underscoring the 
importance of gene dosage in cyst formation [98].  
Conversely, PC2 expression has also been shown to be specifically reduced in mice with biliary 
damage, being modulated post-translationally through the ERAD/proteasome pathway and 
by ER-stressors and NO-donors through the autophagy pathway via post-translational 
modification by ubiquitin [99].  
Siah1 regulates the degradation of endogenous polycystin-1 via the ubiquitin-proteasome 
pathway [100]. The binding of Siah1 to CT1 induces ubiquitination and degradation of PC1 in 
response to cell cycle progression through p21. 
 
Sumoylation 
PC2 has recently been shown to be post-translationally modified by SUMO1 (small ubiquitin-
like modifier 1) protein in arterial smooth muscle cells (myocytes) [101]. At physiological 
intravascular pressures, PC2 exists in approximately equal proportions as either non-
sumoylated or triple SUMO1-modifed proteins. SUMO-PC2 recycles, whereas unmodified PC2 
is surface-resident. Depending on the intravascular pressure and intracellular calcium levels, 
SUMO-PC2 either recycles to the plasma membrane or undergoes degradation in lysosomes. 
This post-translational modification allows the physiological regulation of PC2 surface 




PC1 has been reported to be palmitoylated at its C-terminus, altering its expression levels and 
surface membrane localisation [102]. 
 
Conclusions 
Accumulating evidence has revealed that the polycystin proteins undergo a variety of PTMs 
affecting every aspect of their biology including trafficking, localisation, interaction, channel 
activity, signalling and stability. The best described changes involve phosphorylation, 
glycosylation, proteolytic cleavage and ubiquitination. A key challenge for the future will be 
to elucidate the functional significance of these modifications and their relevance to disease. 
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Figure Legends 
Figure 1. Post-translational modifications are key mechanisms that increase proteomic 
diversity 
While the genome comprises 20,000 to 25,000 genes, the proteome is estimated to 
encompass over 1 million proteins. Changes at the transcriptional and mRNA levels increase 
the size of the transcriptome relative to the genome, and the myriad of different post-
translational modifications exponentially increases the complexity of the proteome relative 
to both the transcriptome and genome. 
 
Figure 2. Experimentally verified polycystin phosphorylation sites 
A total of five phosphorylation sites have been experimentally verified in polycystin-1 and six 
in polycystin-2. A significantly larger number have been identified in high throughput MS 
proteomic screening studies but as of yet have not been verified experimentally 
(https://www.phosphosite.org). Kinases that have been experimentally validated are shown 
above each residue. 
 
Figure 3. Putative role of phosphorylation in the subcellular functions of the polycystins in 
kidney tubular cells 
Phosphorylation at Ser76 is required for PC2 trafficking to or retention at the lateral plasma 
membrane.  Retrograde trafficking of PC2 between plasma membrane, Golgi and ER is 
dependent on Ser812 phosphorylation.  PC2 transport to the ciliary membrane independent of 
Golgi trafficking may occur via an N-terminal RVxP motif; alternatively PC2 complexed to PC1 
could traffic to cilia via a Rabep1/GGA1/Arl3 dependent mechanism (dotted arrows). 
Phosphorylation at Ser829, Ser812 and Ser801 regulates PC2 channel activity. CT1 
phosphorylation can modify GPCR signalling. Phosphorylation of PC1 at Ser3164 (PLAT) 
mediates its internalisation from the plasma membrane. Increased phosphorylation of CT1 
and CT2 at specific residues may result from the loss of Protein Phosphatase-1 (PP1) binding 
to CT1 in PKD1 truncating mutations. 
 
Figure 4. Domain structure of polycystin-1 indicating sites of proteolytic cleavage 
Four putative cleavage sites have been identified in PC1. The GPS site (black arrowhead) has 
been mapped to His Leu Thr  with ci proteolytic cleavage occurring between Leu  
and Thr  Three smaller proteolytic cleavage products of kDa P  kDa and 
kDa CTT  respectively have been reported broken arrows  The blue arrowheads indicate 
 other proteolytic cleavage sites recently reported for PC  present in human urine 







Definition Frequency  
Phosphorylation  
The addition of a phosphate group, usually to 
serine, threonine, and tyrosine 
58383  
Acetylation  
The addition of an acetyl group, either at the N-
terminus of the protein or at lysine residues. 
6751  
N-linked glycosylation  








The addition of an oxygen atom to the side-chain 
of a Pro or Lys residue 
1619  
Methylation  
The addition of a methyl group, usually at lysine 
or arginine residues 
1523  
O-linked glycosylation  




The covalent linkage to the protein ubiquitin 
usually at lysine residues 
878  
Sulfation The addition of a sulfate group to a tyrosine 504  
Sumoylation 
The covalent linkage to the SUMO protein usually 
at lysine residues 
393 
Palmiytoylation 
Attachment of palmitate, a C16 saturated acid 
usually at cysteine residues 
271 
Myristoylation 
Attachment of myristate, a C14 saturated acid 
usually at glycine residues 
140 
Farnesylation 
The addition of an isoprenoid group (e.g. Farnesol 
and geranylgeraniol) usually at cysteine residues 
77 
Deamidation 
The conversion of glutamine to glutamic acid or 
asparagine to aspartic acid 
55 
S-nitrosylation 




Table 1. Common post translational modifications and their experimentally observed 
frequency curated from Swiss-Prot (adapted from Khoury et al. 2011)(46).  
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